REGENXBIO RGNX Stock
REGENXBIO Price Chart
REGENXBIO RGNX Financial and Trading Overview
| REGENXBIO stock price | 13.26 USD |
| Previous Close | 19.69 USD |
| Open | 19.51 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 18.76 - 19.76 USD |
| 52 Week Range | 17.02 - 35.73 USD |
| Volume | 502.52K USD |
| Avg. Volume | 430.22K USD |
| Market Cap | 854.11M USD |
| Beta (5Y Monthly) | 1.046126 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.46 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.36 USD |
RGNX Valuation Measures
| Enterprise Value | 617.33M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.356984 |
| PEG Ratio (5 yr expected) | -0.29 |
| Price/Sales (ttm) | 7.7898545 |
| Price/Book (mrq) | 1.8362769 |
| Enterprise Value/Revenue | 5.63 |
| Enterprise Value/EBITDA | -2.464 |
Trading Information
REGENXBIO Stock Price History
| Beta (5Y Monthly) | 1.046126 |
| 52-Week Change | -6.82% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 35.73 USD |
| 52 Week Low | 17.02 USD |
| 50-Day Moving Average | 19.2 USD |
| 200-Day Moving Average | 22.02 USD |
RGNX Share Statistics
| Avg. Volume (3 month) | 430.22K USD |
| Avg. Daily Volume (10-Days) | 342.11K USD |
| Shares Outstanding | 43.47M |
| Float | 39.26M |
| Short Ratio | 10.4 |
| % Held by Insiders | 7.76% |
| % Held by Institutions | 89.85% |
| Shares Short | 4.79M |
| Short % of Float | 14.32% |
| Short % of Shares Outstanding | 11.02% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -246.50% |
| Operating Margin (ttm) | -241.69% |
| Gross Margin | -160.65% |
| EBITDA Margin | -228.47% |
Management Effectiveness
| Return on Assets (ttm) | -18.68% |
| Return on Equity (ttm) | -46.80% |
Income Statement
| Revenue (ttm) | 109.64M USD |
| Revenue Per Share (ttm) | 2.53 USD |
| Quarterly Revenue Growth (yoy) | -13.90% |
| Gross Profit (ttm) | -184274000 USD |
| EBITDA | -250510000 USD |
| Net Income Avi to Common (ttm) | -270273984 USD |
| Diluted EPS (ttm) | -6.16 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 331.82M USD |
| Total Cash Per Share (mrq) | 7.63 USD |
| Total Debt (mrq) | 93.3M USD |
| Total Debt/Equity (mrq) | 20.06 USD |
| Current Ratio (mrq) | 3.465 |
| Book Value Per Share (mrq) | 10.701 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -232495008 USD |
| Levered Free Cash Flow (ttm) | -169971120 USD |
Profile of REGENXBIO
| Country | United States |
| State | MD |
| City | Rockville |
| Address | 9804 Medical Center Drive |
| ZIP | 20850 |
| Phone | 240 552 8181 |
| Website | https://www.regenxbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 401 |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Q&A For REGENXBIO Stock
What is a current RGNX stock price?
REGENXBIO RGNX stock price today per share is 13.26 USD.
How to purchase REGENXBIO stock?
You can buy RGNX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for REGENXBIO?
The stock symbol or ticker of REGENXBIO is RGNX.
Which industry does the REGENXBIO company belong to?
The REGENXBIO industry is Biotechnology.
How many shares does REGENXBIO have in circulation?
The max supply of REGENXBIO shares is 50.62M.
What is REGENXBIO Price to Earnings Ratio (PE Ratio)?
REGENXBIO PE Ratio is now.
What was REGENXBIO earnings per share over the trailing 12 months (TTM)?
REGENXBIO EPS is -3.46 USD over the trailing 12 months.
Which sector does the REGENXBIO company belong to?
The REGENXBIO sector is Healthcare.
REGENXBIO RGNX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23214.69 USD — |
+0.82
|
6.38B USD — | 23074.39 USD — | 23280.58 USD — | — - | 6.38B USD — |
| US Tech US 700 Small Cap Index NQUS700SC | 2610.16 USD — |
+0.76
|
— — | 2585.44 USD — | 2629.04 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 3446.31 USD — |
+1.07
|
— — | 3418.52 USD — | 3464.76 USD — | — - | — — |
| US Tech Biotechnology NBI | 5813.55 USD — |
+0.87
|
— — | 5757.26 USD — | 5832.47 USD — | — - | — — |
| US Tech Health Care IXHC | 1210.08 USD — |
+0.49
|
— — | 1203.55 USD — | 1213.43 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 28529.37 USD — |
+0.82
|
— — | 28356.95 USD — | 28610.33 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 11381.45 USD — |
+0.82
|
— — | 11312.91 USD — | 11415.04 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}